BioRestorative Therapies (BRTX) Cash & Equivalents (2010 - 2025)

BioRestorative Therapies (BRTX) has 15 years of Cash & Equivalents data on file, last reported at $1.5 million in Q4 2025.

• Quarterly Cash & Equivalents rose 175.82% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (up 175.82% YoY) and the FY2025 annual result came in at $1.5 million, up 175.82% from the prior year.
• Cash & Equivalents climbed to $1.5 million in Q4 2025, from $602444.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $21.0 million in Q4 2021 to a low of $547890.0 in Q4 2024.
• A 5-year average of $5.3 million and a median of $1.8 million in 2021 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents soared 52220.27% — and 2025, when it slumped 91.95%.
• Tracing BRTX's Cash & Equivalents over 5 years: stood at $21.0 million in 2021, then sank by 91.85% to $1.7 million in 2022, then slumped by 48.4% to $884377.0 in 2023, then plunged by 38.05% to $547890.0 in 2024, then jumped by 175.82% to $1.5 million in 2025.
• The last three Cash & Equivalents figures came in at $1.5 million (Q4 2025), $602444.0 (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.